Amphiphilic polymer prodrug for reducing responsive 7-ethyl-10-hydroxycamptothecine and preparation method thereof

A technology of amphiphilic polymers and hydroxycamptothecin, which is applied in the direction of drug combinations, pharmaceutical formulas, and medical preparations of non-active ingredients, etc., can solve the problem of not being able to release the original drug, and achieve mass production and easy availability of raw materials , the effect of high yield and product purity

Active Publication Date: 2019-02-05
烟台药物研究所
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The present invention aims at the deficiency that the polymer drug formed by linking the hydrophilic polymer with the disulfide bond and the hydrophobic drug disclosed in the prior art canno

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Amphiphilic polymer prodrug for reducing responsive 7-ethyl-10-hydroxycamptothecine and preparation method thereof
  • Amphiphilic polymer prodrug for reducing responsive 7-ethyl-10-hydroxycamptothecine and preparation method thereof
  • Amphiphilic polymer prodrug for reducing responsive 7-ethyl-10-hydroxycamptothecine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] A reduction-responsive amphiphilic polymer prodrug of 7-ethyl-10-hydroxycamptothecin has a molecular structure as shown below:

[0041]

[0042] Where n is 40-50.

[0043] The preparation method of above-mentioned amphiphilic polymer prodrug is as follows:

[0044](1) Preparation of TBDPS-7-ethyl-10-hydroxycamptothecin:

[0045] Add 7-ethyl-10-hydroxycamptothecin (2.0 g, 5.1 mmol) into 100 mL of dichloromethane, add triethylamine (3.2 mL, 23 mmol) and TBDPSCl (5.3 mL, 20.4 mmol), and reflux overnight. After cooling to room temperature, the organic phase was washed successively with dilute hydrochloric acid, saturated sodium bicarbonate, and saturated brine, separated, dried, and concentrated under reduced pressure. The concentrated solution was dropped into a large amount of n-hexane for precipitation, filtered, and vacuum-dried to obtain 3.0 g of a yellow solid with a yield of 93%. product 1 H NMR and MS tests showed that TBDPS-7-ethyl-10-hydroxycamptothecin wit...

Embodiment 2

[0056] A reduction-responsive amphiphilic polymer prodrug of 7-ethyl-10-hydroxycamptothecin has a molecular structure as shown below:

[0057]

[0058] where 400

[0059] The preparation method of above-mentioned amphiphilic polymer prodrug is as follows:

[0060] (1) (preparation of TMS-7-ethyl-10-hydroxycamptothecin:

[0061] 7-Ethyl-10-hydroxycamptothecin (2.0 g, 5.1 mmol) was added to 100 mL of dichloromethane, triethylamine (3.2 mL, 23 mmol) and (CH 3 ) 3 SiCl (1.9 mL, 15.3 mmol), reflux overnight. After cooling to room temperature, the organic phase was washed successively with dilute hydrochloric acid, saturated sodium bicarbonate, and saturated brine, separated, dried, and concentrated under reduced pressure. The concentrated solution was dropped into a large amount of n-hexane for precipitation, filtered, and vacuum-dried to obtain 2.19 g of a yellow solid with a yield of 89%.

[0062] (2) (Preparation of TMS-PySS-7-ethyl-10-hydroxycamptothecin:

[006...

Embodiment 3

[0069] A reduction-responsive amphiphilic polymer prodrug of 7-ethyl-10-hydroxycamptothecin has a molecular structure as shown below:

[0070]

[0071] where 500

[0072] The preparation method of above-mentioned amphiphilic polymer prodrug is as follows:

[0073] (1) Preparation of TBDPS-7-ethyl-10-hydroxycamptothecin:

[0074] Add 7-ethyl-10-hydroxycamptothecin (2.0 g, 5.1 mmol) into 100 mL of dichloromethane, add triethylamine (3.2 mL, 23 mmol) and TBDPSCl (1.3 mL, 5.1 mmol), and reflux overnight. After cooling to room temperature, the organic phase was washed successively with dilute hydrochloric acid, saturated sodium bicarbonate, and saturated brine, separated, dried, and concentrated under reduced pressure. The concentrated solution was dropped into a large amount of n-hexane for precipitation, filtered, and vacuum-dried to obtain 2.6 g of a yellow solid with a yield of 81%. product 1 H NMR and MS tests showed that TBDPS-7-ethyl-10-hydroxycamptothecin was...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Half inhibitory rateaaaaaaaaaa
Login to view more

Abstract

The invention relates to an amphiphilic polymer prodrug for reducing responsive 7-ethyl-10-hydroxycamptothecine and a preparation method thereof. The amphiphilic polymer prodrug has the molecular structure as shown in the specification, wherein the polymerization degree n is 5-1000 and m is 1 or 2. According to the prodrug, targeted drug delivery can be realized, and therefore the advantages of anano drug carrier system are kept, and meanwhile, the characteristic that a disulfide bond is specifically degraded in a tumor site can be achieved. Compared with conventional 2,2'-disulfanediyldiacetic acid, 3,3'-dithiodipropionic acid and other connecting arms, the prodrug and the preparation method thereof have the advantage that an anticancer drug in an active compound molecular form can be obtained without further hydrolysis.

Description

technical field [0001] The invention relates to an amphiphilic polymer drug prodrug and a preparation method thereof, in particular to an amphiphilic polymer drug prodrug of 7-ethyl-10-hydroxycamptothecin and a preparation method thereof. Background technique [0002] Chemotherapy is a basic tumor treatment method, which mainly uses anticancer drugs to kill tumor cells to achieve the purpose of treating tumors. Clinically commonly used anticancer drugs mainly include camptothecins, taxanes, vinblastine, and anthraquinones, etc., but these anticancer drugs have poor physical and chemical properties (such as insoluble in water, poor selectivity, etc.), and are not effective for normal The cells and tissues have serious toxic and side effects, resulting in poor tumor chemotherapy effect, so the clinical application is limited. [0003] 7-Ethyl-10-hydroxycamptothecin (abbreviated as SN-38) is one of the important derivatives of camptothecin drugs. SN-38 is a metabolite of irin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4745A61K9/107A61K47/14A61P35/00C08G65/334
CPCA61K9/1075A61K31/4745A61K47/14C08G65/3348
Inventor 任春光李亚平孔德旭李泽民栾委静李暖暖李艺张丽谢洪磊李双民
Owner 烟台药物研究所
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products